Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401461 | PMC |
| http://dx.doi.org/10.1016/j.invent.2024.100749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 immunorad conference.
Oncoimmunology
December 2025
Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer.
View Article and Find Full Text PDFPotential Therapeutic Benefit of the Selective Inhibitors of Casitas B Cell Lymphoma-b (CBL-B) in Cancer Immunotherapy.
ACS Med Chem Lett
December 2024
PI Health Sciences, 100 Jade Park, Chelsea, Alabama 35043, United State.
The invention in this patent application relates to 1,6-dihydro-7-pyrrolo[2,3-]pyridin-7-one derivatives represented generally by formula 1. These compounds are inhibitors of the E3 ubiquitin ligase, casitas B-lineage lymphoma proto-oncogene-b (CBL-B), and may be useful for the treatment of immunosuppression-associated diseases and disorders such as cancer and chronic viral infections.
View Article and Find Full Text PDFInhibition of the Binding of Interleukin 17A with Interleukin 17A Receptor as a Treatment for Immune System and Inflammation Disorders, Cancer, and Neurodegenerative Diseases.
ACS Med Chem Lett
December 2024
PI Health Sciences, 100 Jade Park, Chelsea, Alabama 35043, United States.
The invention in this patent application relates to -(2-amino-2-oxoethyl)heteroarylcarboxamide derivatives, represented herein generally by formula 1. These compounds are inhibitors of the binding of interleukin 17A (IL-17A) with its receptor IL-17RA and may potentially be used for the treatment of diseases or disorders associated with IL-17A activity, which include psoriasis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis, cancer, and neurodegenerative disorders.
View Article and Find Full Text PDFInnovative Cancer Therapies: Targeting Oncogenic Pathways through Placental Immunology, PROTAC Technology, and Kinase Degradation.
ACS Med Chem Lett
December 2024
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
Recent advancements in cancer therapy have led to groundbreaking approaches targeting critical oncogenic pathways. This Patent Highlight explores four essential patents that focus on modulating ligand-receptor interactions from placental immunology, degrading RAF proteins with MEK1/2 degraders, and employing PROTAC technology to degrade Cyclin D, CDK4, and CDK6 proteins. These innovations aim to overcome traditional therapy limitations and address resistance in cancers such as breast, lung, and RAS-altered cancers.
View Article and Find Full Text PDFBladder cancer biomarkers: current approaches and future directions.
Front Oncol
November 2024
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Bladder cancer is a significant health concern worldwide, necessitating effective diagnostic and monitoring strategies. Biomarkers play a crucial role in the early detection, prognosis, and treatment of this disease. This review explores the current landscape of bladder cancer biomarkers, including FDA-approved molecular biomarkers and emerging ones.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!